KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Nov-2023
Active ingredients
pembrolizumab
Proposed indication
For the treatment of patients with high-risk, locally advanced cervical cancer.
Application type
C (new indication)
Publication date
Nov-2023